Merus N.V.

MRUS

$90.00

Name : Merus N.V.

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $6,826,245,632.00

EPSttm : -5.28

Merus N.V.

$90.00

0.00%

$0.00000000000000

Float Short %

2.59

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

-0.09

EPS Last/This Y

-2.37

EPS This/Next Y

0.59

Price

Target Price

Analyst Recom

2.75

Performance Q

-3.92

Relative Volume

Beta

1.19

Ticker: MRUS

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-12-10	MRUS	96.77	1.67	0.63	57590
2025-12-11	MRUS	96.65	1.67	1.86	58124
2025-12-12	MRUS	96.91	1.73	31.79	58848
2025-12-15	MRUS	96.83	1.86	2.24	60538
2025-12-16	MRUS	96.91	1.78	1.66	59855
2025-12-17	MRUS	96.91	1.82	34.56	60184
2025-12-18	MRUS	96.83	1.84	0.75	60676
2025-12-19	MRUS	96.93	1.81	1.93	61399
2025-12-22	MRUS	96.96	1.75	10.06	42279
2025-12-23	MRUS	96.93	1.78	0.10	42260
2025-12-26	MRUS	96.93	1.67	0.02	44281
2025-12-29	MRUS	89.73	2.09	0.25	41736
2025-12-30	MRUS	90	2.09	0.37	41736
2025-12-31	MRUS	90	2.09	0.37	41736
2026-01-02	MRUS	90	2.09	0.37	41736
2026-01-05	MRUS	90	2.09	0.37	41736
2026-01-06	MRUS	90	N/A	N/A	0
2026-01-07	MRUS	90	N/A	N/A	0
2026-01-08	MRUS	90	N/A	N/A	0
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

16 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-12-10	MRUS	96.79	-116.3	0.1	-5.68
2025-12-11	MRUS	96.66	-116.3	2.4	-5.68
2025-12-12	MRUS	96.91	-116.3	0.7	-5.68
2025-12-15	MRUS	96.82	-116.3	2.4	-5.68
2025-12-16	MRUS	96.82	-116.3	2.0	-5.68
2025-12-17	MRUS	96.90	-116.3	2.0	-5.68
2025-12-18	MRUS	96.84	-116.3	2.2	-5.68
2025-12-19	MRUS	96.93	-116.3	1.5	-5.68
2025-12-22	MRUS	96.95	-116.3	1.8	-5.68
2025-12-23	MRUS	96.92	-116.3	2.1	-5.68
2025-12-26	MRUS	96.93	-116.3	1.8	-5.68
2025-12-29	MRUS	90.00	-116.3	30.7	-5.68
2025-12-30	MRUS	90.00	-116.3	1.9	-5.68
2025-12-31	MRUS	90.00	-116.3	1.9	-5.68
2026-01-02	MRUS	90.00	-108.6	1.9	-5.72
2026-01-05	MRUS	90.00	-102.7	1.9	-5.72
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

16 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-12-10	MRUS	-1.54	-7.49	2.24
2025-12-11	MRUS	-1.57	-7.49	2.24
2025-12-12	MRUS	-1.57	-7.49	2.24
2025-12-15	MRUS	-1.58	-7.38	2.24
2025-12-16	MRUS	-1.58	-7.38	2.24
2025-12-17	MRUS	-1.58	-7.38	2.24
2025-12-18	MRUS	-1.58	-7.38	2.24
2025-12-19	MRUS	3.20	-7.38	2.24
2025-12-22	MRUS	3.30	-7.37	4.98
2025-12-23	MRUS	1.04	-7.37	4.98
2025-12-26	MRUS	1.12	-7.37	2.59
2025-12-29	MRUS	1.12	-7.38	2.59
2025-12-30	MRUS	3.04	-7.38	2.59
2025-12-31	MRUS	5.63	-7.38	2.59
2026-01-02	MRUS	5.63	-7.38	2.59
2026-01-05	MRUS	5.63	0	2.59
2026-01-06	MRUS	5.63	0	2.59
2026-01-07	MRUS	5.63	0	2.59
2026-01-08	MRUS	5.63	0	2.59
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

-1.23

Avg. EPS Est. Current Quarter

-1.02

Avg. EPS Est. Next Quarter

-1.32

Insider Transactions

5.63

Institutional Transactions

Beta

1.19

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

7.3

Max Drawdown 5-Year %

-60.4

Target Price

P/E

Forward P/E

PEG

P/S

120.59

P/B

8.81

P/Free Cash Flow

EPS

-5.33

Average EPS Est. Cur. Y

-5.72

EPS Next Y. (Est.)

-5.14

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-673.31

Relative Volume

Return on Equity vs Sector %

-76.5

Return on Equity vs Industry %

-61.1

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.04

EBIT Estimation

1.9

Merus N.V.

Sector: Healthcare

Industry: Biotechnology

Employees: 260

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1. The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the treatment of patients with lungs and other solid tumors; ONO-4685 to treat relapsed/refractory T cell lymphoma; and INCA33890 for advanced solid tumors. In addition, it has collaboration agreement with Eli Lilly and Company, Ono Pharmaceutical Co., Ltd., and Betta Pharmaceuticals Co. Ltd. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands. As of December 11, 2025, Merus N.V. operates as a subsidiary of Genmab A/S.

stock quote shares MRUS – Merus N.V Stock Price stock today

news today MRUS – Merus N.V stock forecast ,stock prediction 2023 2024 2025

marketwatch MRUS – Merus N.V yahoo finance google finance

stock history MRUS – Merus N.V invest stock market

stock prices MRUS premarket after hours

ticker MRUS fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: MRUS

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y